Alglucosidase Alfa (Lumizyme)

Lumizyme (alglucosidase alfa) is covered only for the FDA‑approved indication of Pompe disease; off‑label uses are excluded. Coverage requires confirmed diagnosis by alpha‑glucosidase enzyme assay or genetic testing with documentation, authorization is for up to 12 months, and prescribers must observe safety monitoring for anaphylaxis, immune‑mediated reactions, and fluid/respiratory/cardiac risks (especially in infantile‑onset or compromised patients).

"Lumizyme (alglucosidase alfa) is indicated for the treatment of individuals with Pompe disease."

Sign up to see full coverage criteria, indications, and limitations.